# Oncolytic Virus Sector

Canonical URL: https://biopharmsignal.com/sector/oncolytic-virus

Oncolytic Virus includes companies using tumor-targeting viruses to directly kill cancer cells or stimulate anti-tumor immunity. The category remains important because it sits at the intersection of virology, immunotherapy, and combination oncology strategies.

Companies currently grouped under Oncolytic Virus: 1

## Recent Sector News

- 2026-09-29 13:30 EST — ONCY — [Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-publication-demonstrating-pelareorep-creates-immune-77c2c304) — Source: Oncolytics Biotech Inc.
- 2026-09-28 13:30 EST — ONCY — [Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mut-c5320cbe) — Source: Oncolytics Biotech Inc.
- 2026-09-10 12:15 EST — ONCY — [Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-positive-preclinical-results-combining-pelareorep-w-cffe8027) — Source: Oncolytics Biotech Inc.
- 2026-08-18 13:00 EST — ONCY — [Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-aligns-with-fda-on-registrational-path-for-second-line-ras-mu-9d983733) — Source: Oncolytics Biotech Inc.
- 2026-07-20 13:00 EST — ONCY — [Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-receives-fast-track-designation-for-pelareorep-in-second-line-a2a9c705) — Source: Oncolytics Biotech Inc.
- 2026-07-13 13:00 EST — ONCY — [Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-clinical-progress-ed86b993) — Source: Oncolytics Biotech Inc.
- 2026-06-16 13:00 EST — ONCY — [Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-secures-new-u-s-patent-protecting-commercial-manufacturing-of-006020e4) — Source: Oncolytics Biotech Inc.
- 2026-06-02 13:00 EST — ONCY — [Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-appointment-of-steve-glover-to-board-of-directors-a-23493926) — Source: Oncolytics Biotech Inc.
- 2026-06-01 13:00 EST — ONCY — [Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-positive-initial-preclinical-findings-supporting-fu-5be55556) — Source: Oncolytics Biotech Inc.
- 2026-05-22 13:00 EST — ONCY — [Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-present-data-at-asco-2026-reinforcing-pelareorep-s-potenti-ae06f28b) — Source: Oncolytics Biotech Inc.
- 2026-05-04 13:00 EST — ONCY — [Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-color-de371576) — Source: Oncolytics Biotech Inc.
- 2026-04-27 12:10 EST — ONCY — [Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study](https://biopharmsignal.com/news/ONCY/oncolytics-aligns-with-fda-on-planned-pivotal-anal-cancer-study-408d9262) — Source: Oncolytics Biotech Inc.
- 2026-04-06 13:00 EST — ONCY — [Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-type-c-fda-meeting-to-discuss-single-arm-registrati-546e0240) — Source: Oncolytics Biotech Inc.
- 2026-04-01 13:00 EST — ONCY — [Oncolytics Biotech® Completes Domicile Change to the United States](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-completes-domicile-change-to-the-united-states-ff8a9f89) — Source: Oncolytics Biotech Inc.
- 2026-03-19 13:00 EST — ONCY — [Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-present-new-mechanistic-and-translational-data-supporting--1f7a745b) — Source: Oncolytics Biotech Inc.
- 2026-03-02 14:00 EST — ONCY — [Oncolytics Biotech® Launches Randomized Colorectal Cancer Study](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-launches-randomized-colorectal-cancer-study-a171785c) — Source: Oncolytics Biotech Inc.
- 2026-02-24 14:00 EST — ONCY — [Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-to-prioritize-registration-focused-programs-in-anal-and-color-88555fbe) — Source: Oncolytics Biotech Inc.
- 2026-02-04 13:50 EST — ONCY — [Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-receives-fda-fast-track-designation-for-pelareorep-in-2l-kras-09e05c04) — Source: Oncolytics Biotech Inc.
- 2026-01-15 21:01 EST — ONCY — [Oncolytics Biotech® Announces Results of Special Meeting of Shareholders](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders-508804b7) — Source: Oncolytics Biotech Inc.
- 2026-01-14 14:00 EST — ONCY — [Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-y-03a3bea3) — Source: Oncolytics Biotech Inc.

## Companies

- [ONCY](https://biopharmsignal.com/company/ONCY) — Oncolytics Biotech Inc.